Considering the importance of T-DM1 in treatment of HER2+ cancers, and the potential for future combination treatments with actin-targeting drugs, we next examined the response of HER2+ cancer cells to combination treatments with Myc B and T-DM1. Here, ERBB2 is linked to cancer.